Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Frankfurt - Delayed Quote EUR

Eli Lilly and Company (LLY0.F)

Compare

21.20

-0.20

(-0.93%)

At close: February 28 at 3:29:01 PM GMT+1

Eli Lilly's (NYSE:LLY) Earnings May Just Be The Starting Point

Eli Lilly and Company ( NYSE:LLY ) just reported healthy earnings but the stock price didn't move much. We think that...

Simply Wall St. 7 hours ago

LLY
Eli Lilly comes for knockoff weight loss drugs in new ad campaign

Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, launched a new advertising campaign on Friday warning patients about off-brand versions of its treatments, saying “they put people at risk.”

Quartz 7 hours ago

LLY
Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up

Hims & Hers Health put out a jaw dropping commercial. Now, Hims stock is just dropping, as its semaglutide business faces a setback.

Investor's Business Daily 10 hours ago

NONOF

NVO

HIMS
Lilly to participate in Leerink Partners Global Healthcare Conference

Eli Lilly and Company (NYSE: LLY) will participate in Leerink Partners Global Healthcare Conference on March 10, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in a fireside chat at 9:20 a.m., Eastern time.

PR Newswire 12 hours ago

LLY
Pharma Stock Roundup: LLY Ups U.S. Manufacturing Investments & More

LLY is increasing its manufacturing capacity in the United States by building four new plants. AZN's phase III study on camizestrant meets primary endpoint.

Zacks 12 hours ago

LLY

AZN
Eli Lilly Doubles Capital Spending On US Drug Manufacturing With $50 Billion Target (CORRECTED)

Editor’s Note: The story has been updated to correct the new site locations At a press conference in Washington, D.C., Eli Lilly And Co (NYSE:LLY) announced its plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States. The company is currently negotiating with several states. The company’s previous total domestic capital expansion commitments from 2020 to 2024 totaled $23 billion. This brings the compa

Benzinga 12 hours ago

LLY
$Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor$

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have been previously treated with a BTK inhibitor.

PR Newswire 13 hours ago

LLY
How To Buy And Sell Stocks: This Table Finds Important Stock Moves

How To Buy And Sell Stocks: Use this IBD table to find stocks that are moving up and down in heavy volume on the stock market today.

Investor's Business Daily 14 hours ago

TCOM

TRPCF

LLY
Drug Stocks Are the New Safe Bet in a Shaky Market

After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

The Wall Street Journal 15 hours ago

LLY
Praxis hits trial setback; Bristol Myers lays off staff in New Jersey

The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly struck a molecular glue deal and Zevra sold a priority review voucher.

BioPharma Dive 15 hours ago

CELG-RT

PRAX

ZVRA
Eli Lilly's big investment, cheaper Zepbound, and what's next for Hims & Hers: Pharma news roundup

Eli Lilly announced plans to invest $27 billion in four new manufacturing sites in the United States. The pharma giant also made a wider range of doses of its blockbuster weight-loss drug Zepbound available in vials and at lower prices. Meanwhile, Hims & Hers, which profited heavily last year from selling an off-brand version of Ozempic, is now exploring alternative options after being forced to halt sales.

Quartz 17 hours ago

LLY
Top Research Reports for Amazon, Eli Lilly & S&P Global

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Eli Lilly and Co. (LLY) and S&P Global Inc. (SPGI), as well as a micro-cap stock CVD Equipment Corporation (CVV).

Zacks yesterday

LLY

AMZN

SYK
Eli Lilly wants to make drugs in America. First it wants a tax cut

Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, announced Wednesday that it plans to invest $27 billion in four new manufacturing sites in the United States. But the company made it clear that those plans hinge on tax cuts.

Quartz yesterday

LLY
Eli Lilly investing $27B more in US manufacturing

Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.

Fox Business yesterday

LLY
Nvidia and Trump Tariffs Are Competing for Market’s Attention. Why AI Is Winning and 5 Other Things to Know Today.

Tesla stock’s tumble has hit Musk’s wealth hard, Eli Lilly is doubling down on U.S. factories amid trade threat, and more news to start your day.

Barrons.com yesterday

NVDA

LLY

TSLA
Eli Lilly to expand US pharma manufacturing with four new sites

The move increases the company's total capital expansion commitments in the US to above $50bn since 2020.

Pharmaceutical Technology yesterday

LLY
What Eli Lilly's $27B investment in US manufacturing means for GLP-1s

Mizuho healthcare equity strategist Jared Holz joins Julie Hyman and Josh Lipton on Market Domination to analyze the GLP-1 weight-loss drug market following Eli Lilly's (LLY) announcement of a substantial $27 billion investment in US manufacturing. Eli Lilly makes the weight-loss drugs Mounjaro and Zepbound. Holz highlights two significant implications of this investment: first, it could boost domestic production capacity for these increasingly popular medications; second, it might "circumvent or alleviate any tariff issues" related to these drugs, potentially creating supply chain advantages. Regarding consumer pricing, Holz says the "trajectory of these GLP-1s in terms of pricing is definitely down," noting Eli Lilly's ongoing efforts to improve patient affordability. Despite potential price reductions, Holz emphasizes the medications' extensive benefits beyond weight loss, including improved cardiovascular health, reduced stroke risk, and anti-inflammatory effects. Given this, he argues the drugs remain "very, very cheap" at current price points when you "look at what the drug can do in totality." Holz predicts a pill form of GLP-1s could come to market by 2027. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Angel Smith

Yahoo Finance Video 2 days ago

LLY

NOV
Eli Lilly to invest $27B in new US manufacturing plants

Eli Lilly (LLY) announces it will invest $27 billion in four new manufacturing sites in the US. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to break down the news. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Naomi Buchanan.

Yahoo Finance Video 2 days ago

LLY
Eli Lilly Plans 4 New US Manufacturing Sites With $27 Billion Investment

Eli Lilly (LLY) on Wednesday outlined a plan to invest at least $27 billion to build four new pharma

PREMIUM
MT Newswires 2 days ago

LLY
Eli Lilly Latest US Company to Commit to Domestic Investments

Eli Lilly plans to invest at least $27 billion to build four new manufacturing sites in the U.S., a week after President Trump reportedly said he planned to impose tariffs of 25% or more on pharmaceutical imports.

Investopedia 2 days ago

LLY

AAPL

Performance Overview

Return	LLY0.F	S&P 500
YTD	+14.87%	+1.24%
1-Year	+11.26%	+17.45%
3-Year	+8.74%	+36.14%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Eli Lilly and Company (LLY0.F)

Eli Lilly's (NYSE:LLY) Earnings May Just Be The Starting Point

Eli Lilly comes for knockoff weight loss drugs in new ad campaign

Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up

Lilly to participate in Leerink Partners Global Healthcare Conference

Pharma Stock Roundup: LLY Ups U.S. Manufacturing Investments & More

Eli Lilly Doubles Capital Spending On US Drug Manufacturing With $50 Billion Target (CORRECTED)

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

How To Buy And Sell Stocks: This Table Finds Important Stock Moves

Drug Stocks Are the New Safe Bet in a Shaky Market

Praxis hits trial setback; Bristol Myers lays off staff in New Jersey

Eli Lilly's big investment, cheaper Zepbound, and what's next for Hims & Hers: Pharma news roundup

Top Research Reports for Amazon, Eli Lilly & S&P Global

Eli Lilly wants to make drugs in America. First it wants a tax cut

Eli Lilly investing $27B more in US manufacturing

Nvidia and Trump Tariffs Are Competing for Market’s Attention. Why AI Is Winning and 5 Other Things to Know Today.

Eli Lilly to expand US pharma manufacturing with four new sites

What Eli Lilly's $27B investment in US manufacturing means for GLP-1s

Eli Lilly to invest $27B in new US manufacturing plants

Eli Lilly Plans 4 New US Manufacturing Sites With $27 Billion Investment

Eli Lilly Latest US Company to Commit to Domestic Investments

Performance Overview